Stephen Liu on a paper by Natasha Leighl, et al.

Stephen Liu recently shared a post on X:

“PALOMA-3 results at Journal of Clinical Oncology after ASCO24 oral presentation.

Subcutaneous vs intravenous amivantamab (with lazertinib) in previously treated EGFR NSCLC (n=418). The primary PK endpoint shows non-inferiority. Subcutaneous with a much better safety profile.

Subcutaneous amivantamab with lower rate of infusion reactions (13% vs 66%) and the reactions seen were far less severe.

Lower rates of VTE with subcutaneous. Much faster and more convenient. Similar RR. PFS is numerically longer. OS better with subcutaneous (HR 0.62, exploratory).”

Read further
Source: Stephen Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.